EP3322444A4 - Agent thérapeutique pour tumeur comprenant un inhibiteur de l'ido administré en association avec un anticorps - Google Patents

Agent thérapeutique pour tumeur comprenant un inhibiteur de l'ido administré en association avec un anticorps Download PDF

Info

Publication number
EP3322444A4
EP3322444A4 EP16824090.1A EP16824090A EP3322444A4 EP 3322444 A4 EP3322444 A4 EP 3322444A4 EP 16824090 A EP16824090 A EP 16824090A EP 3322444 A4 EP3322444 A4 EP 3322444A4
Authority
EP
European Patent Office
Prior art keywords
antibody
association
therapeutic agent
ido inhibitor
inhibitor administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16824090.1A
Other languages
German (de)
English (en)
Other versions
EP3322444A1 (fr
Inventor
Akihiro TOKUNAGA
Toshihiko Ishii
Motoya Mie
Munetoshi Ando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Priority to EP21199914.9A priority Critical patent/EP3991749A3/fr
Publication of EP3322444A1 publication Critical patent/EP3322444A1/fr
Publication of EP3322444A4 publication Critical patent/EP3322444A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
EP16824090.1A 2015-07-14 2016-07-14 Agent thérapeutique pour tumeur comprenant un inhibiteur de l'ido administré en association avec un anticorps Withdrawn EP3322444A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP21199914.9A EP3991749A3 (fr) 2015-07-14 2016-07-14 Agent thérapeutique pour tumeur comprenant un inhibiteur de l'ido administré en association avec un anticorps

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562192173P 2015-07-14 2015-07-14
PCT/JP2016/003337 WO2017010106A1 (fr) 2015-07-14 2016-07-14 Agent thérapeutique pour tumeur comprenant un inhibiteur de l'ido administré en association avec un anticorps

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP21199914.9A Division EP3991749A3 (fr) 2015-07-14 2016-07-14 Agent thérapeutique pour tumeur comprenant un inhibiteur de l'ido administré en association avec un anticorps

Publications (2)

Publication Number Publication Date
EP3322444A1 EP3322444A1 (fr) 2018-05-23
EP3322444A4 true EP3322444A4 (fr) 2019-06-12

Family

ID=57757291

Family Applications (2)

Application Number Title Priority Date Filing Date
EP21199914.9A Pending EP3991749A3 (fr) 2015-07-14 2016-07-14 Agent thérapeutique pour tumeur comprenant un inhibiteur de l'ido administré en association avec un anticorps
EP16824090.1A Withdrawn EP3322444A4 (fr) 2015-07-14 2016-07-14 Agent thérapeutique pour tumeur comprenant un inhibiteur de l'ido administré en association avec un anticorps

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP21199914.9A Pending EP3991749A3 (fr) 2015-07-14 2016-07-14 Agent thérapeutique pour tumeur comprenant un inhibiteur de l'ido administré en association avec un anticorps

Country Status (10)

Country Link
US (2) US20180271861A1 (fr)
EP (2) EP3991749A3 (fr)
JP (2) JP2018524361A (fr)
KR (1) KR102823683B1 (fr)
CN (1) CN107847597A (fr)
AU (1) AU2016293667A1 (fr)
CA (1) CA2992238A1 (fr)
HK (1) HK1252514A1 (fr)
TW (1) TW201713332A (fr)
WO (1) WO2017010106A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021500916A (ja) 2017-07-28 2021-01-14 フェインズ セラピューティクス，インコーポレーテッド 抗ｔｉｍ−３抗体及びその使用
MX2021002302A (es) * 2018-08-29 2021-04-28 Chemocentryx Inc Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control.
US11839659B2 (en) 2020-07-02 2023-12-12 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein
CN112961239B (zh) * 2021-02-24 2021-09-10 北京昭衍生物技术有限公司 Tim抑制剂及其应用
BR112023017582A2 (pt) 2021-03-05 2023-12-05 Univ Basel Composições para o tratamento de doenças ou condições associadas ao ebv
EP4052705A1 (fr) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions pour le traitement des maladies ou des pathologies associées à l'ebv

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186035A1 (fr) * 2013-03-14 2014-11-20 Curadev Pharma Private Ltd. Inhibiteurs de la voie de la kynurénine
WO2015070007A1 (fr) * 2013-11-08 2015-05-14 Incyte Corporation Procédé pour la synthèse d'un inhibiteur de l'indoleamine 2,3-dioxygénase

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677A (en) 1848-07-25 Improvement in hillside-plows
US171A (en) 1837-04-20 Machine for washing iron and other ores
US4968A (en) 1847-02-13 Spinal elevator
US603A (en) 1838-02-15 Improvement in the construction of many-chambered fire-arms
US5821A (en) 1848-10-03 Cream-freezer
US337A (en) 1837-07-31 Mode of constructing railroad-frogs
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US6395876B1 (en) 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
SI1270595T1 (sl) 2000-03-03 2008-12-31 Kyowa Hakko Kogyo Kk Protitelo proti CCR4 in njegov fragment
CN100430420C (zh) 2001-08-31 2008-11-05 协和发酵工业株式会社 人cdr-移植抗体及其抗体片段
JP4694128B2 (ja) 2002-01-30 2011-06-08 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ＴＩＭ−３、Ｔｈ１特異的細胞表面分子に関連した組成物および方法
WO2005057341A2 (fr) 2003-12-02 2005-06-23 Koolspan, Inc. Systeme de reseau prive virtuel active par du materiel automatique
DK1879573T3 (da) 2005-05-10 2013-02-25 Incyte Corp Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
CA2682382A1 (fr) * 2007-03-28 2008-10-09 Biogen Idec Inc. Anticorps non fucosyles
CA2711370C (fr) 2008-01-15 2017-06-13 The Board Of Trustees Of The Leland Stanford Junior University Marqueurs des cellules souches de la leucemie myeloide aigue
CA3012229C (fr) * 2008-07-08 2020-11-10 Incyte Holdings Corporation 1,2,5-oxadiazoles constituant des inhibiteurs de l'indoleamine 2,3-dioxygenase
WO2010053182A1 (fr) 2008-11-10 2010-05-14 協和発酵キリン株式会社 Inhibiteur de production de kynurénine
ES2550639T3 (es) * 2009-04-27 2015-11-11 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-IL-3Ralfa para su utilización en el tratamiento de un tumor de la sangre
EP2476438B1 (fr) 2009-09-10 2014-07-23 Kyowa Hakko Kirin Co., Ltd. Médicament comprenant une composition d'anticorps liée spécifiquement au récepteur de chimiokine cc4 humain (ccr4)
WO2011042065A1 (fr) 2009-10-09 2011-04-14 Daniel Monsch Module d'élévation « momoheli » et véhicules
TWI535442B (zh) * 2010-05-10 2016-06-01 Kyowa Hakko Kirin Co Ltd A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
CN103079644B (zh) * 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
ES2903205T3 (es) 2011-11-09 2022-03-31 Kyowa Kirin Co Ltd Compuestos heterocíclicos que contienen nitrógeno
CN104884617B (zh) * 2012-12-07 2019-02-19 协和发酵麒麟株式会社 抗folr1抗体
CN105473550B (zh) 2013-07-01 2019-02-15 百时美施贵宝公司 Ido抑制剂
US20170247449A1 (en) 2014-06-06 2017-08-31 Kyowa Hakko Kirin Co., Ltd Therapeutic method and medicament for cancer patients by folr1-targeting drug and an antagonist for folic acid metabolism

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014186035A1 (fr) * 2013-03-14 2014-11-20 Curadev Pharma Private Ltd. Inhibiteurs de la voie de la kynurénine
WO2015070007A1 (fr) * 2013-11-08 2015-05-14 Incyte Corporation Procédé pour la synthèse d'un inhibiteur de l'indoleamine 2,3-dioxygénase

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. OGURA ET AL: "Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma", JOURNAL OF CLINICAL ONCOLOGY, vol. 32, no. 11, 10 April 2014 (2014-04-10), US, pages 1157 - 1163, XP055345042, ISSN: 0732-183X, DOI: 10.1200/JCO.2013.52.0924 *
RIKKE B. HOLMGAARD ET AL: "Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 210, no. 7, 10 June 2013 (2013-06-10), US, pages 1389 - 1402, XP055545183, ISSN: 0022-1007, DOI: 10.1084/jem.20130066 *

Also Published As

Publication number Publication date
JP7366093B2 (ja) 2023-10-20
AU2016293667A1 (en) 2018-01-04
CA2992238A1 (fr) 2017-01-19
EP3991749A3 (fr) 2022-08-24
JP2021191780A (ja) 2021-12-16
EP3991749A2 (fr) 2022-05-04
EP3322444A1 (fr) 2018-05-23
US20180271861A1 (en) 2018-09-27
JP2018524361A (ja) 2018-08-30
KR102823683B1 (ko) 2025-06-23
US20220088011A1 (en) 2022-03-24
CN107847597A (zh) 2018-03-27
KR20180025897A (ko) 2018-03-09
HK1252514A1 (zh) 2019-05-31
TW201713332A (zh) 2017-04-16
WO2017010106A1 (fr) 2017-01-19

Similar Documents

Publication Publication Date Title
EP3612181A4 (fr) Thérapies d'association avec des inhibiteurs d'ehmt2
GB201820166D0 (en) Therapeutic agents
MA56006A (fr) Formulations sous-cutanées d'anticorps her2
EP3510161A4 (fr) Compositions et méthodes pour traiter une déficience auditive non associée à l'âge chez un sujet humain
EP3291765A4 (fr) Procédés d'administration d'un agent à l'oeil
EP3307371A4 (fr) Cathéter avec géométrie pré-formée pour l'accès à une lumière corporelle.
MA44054A (fr) Plateforme d'anticorps bispécifique
EP3478314A4 (fr) Conjugués pour l'édition de surface cellulaire ciblée
TN2019000033A1 (fr) Agents thérapeutiques pour maladies neurodégénératives
EP3324973A4 (fr) Systèmes et procédés pour le traitement de l' il avec un photosensibilisateur
MA43402A (fr) Composition pharmaceutique comprenant un inhibiteur puissant d'urat1
EP3316885A4 (fr) Immunoconjugués d'anticorps sn-38 avec un lieur cl2a
EP3489936A4 (fr) Corps d'affichage
EP3419728A4 (fr) Configuration de sessions de jeu pour réduire le temps d'attente
MA41159A (fr) Octréotide destiné à être administré par voie orale en association avec d'autres agents thérapeutiques
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
EP3302554A4 (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
EP3370725A4 (fr) Dosage pédiatrique pour le traitement du cancer avec un inhibiteur d'ezh2
EP3458060A4 (fr) Polythérapie pour un dysfonctionnement sexuel chez l'homme
EP3005907A4 (fr) Matelas pour réunir et répartir de façon uniforme la gravité d'un corps humain
GB201805816D0 (en) Therapeutic agents
SG11201601306QA (en) An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
EP3313380A4 (fr) Composition pour l'administration d'agents actifs à un animal
EP3302557A4 (fr) Amélioration de l'activité thérapeutique d'un inhibiteur de point de contrôle immunitaire
MA43758A (fr) Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180214

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/498 20060101ALI20190130BHEP

Ipc: A61K 39/395 20060101AFI20190130BHEP

Ipc: A61P 35/00 20060101ALI20190130BHEP

Ipc: A61K 45/00 20060101ALI20190130BHEP

Ipc: A61P 35/02 20060101ALI20190130BHEP

Ipc: A61K 31/4245 20060101ALI20190130BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1252514

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20190510

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/02 20060101ALI20190506BHEP

Ipc: A61K 39/395 20060101AFI20190506BHEP

Ipc: A61K 45/00 20060101ALI20190506BHEP

Ipc: A61P 35/00 20060101ALI20190506BHEP

Ipc: A61K 31/498 20060101ALI20190506BHEP

Ipc: A61K 31/4245 20060101ALI20190506BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KYOWA KIRIN CO., LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200709

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210930

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1252514

Country of ref document: HK